• Optimi Health Corp. Common Shares is trading 12.1% up at $5.39 in pre-market, extending a sharp 16.6% after-hours spike.
  • The price surge follows growing investor confidence in the company's expanding commercial psychedelic medicine operations, as reported on June 15, 2026.
  • Recent catalysts include the completion of its first export of naturally derived psilocybin to the United Kingdom for a Phase 2 clinical trial on June 10, 2026, and securing ibogaine supply on June 8, 2026.